Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There definitely has been steady buying this week. Maybe we will hear something soon from Holigan about his plans.
I think that Coca-Cola should buy Pompis along with Monster and call it Monster Pompis...lol
Kim Kardashian could be the spokesperson.
Seriously though this is turning out to be a much longer term investment for me due to the Pom not so Wonderful lawsuit.
Let us hope for a settlement soon.
I agree Bama that since MH is still battling it out in the face of increasing legal fees means that he believes that the fight is worth it in the end. He has too much money invested in the marketing of the Pompis brand to change the name now, IMO. In marketing the branding is of paramount importance. His continuing to fight could also mean that Pompis is very profitable and he is using the profits to pay the legal fees.
Also he is probably factoring in the fact that he only paid $30k for the shell which was a bargain for a clean shell. Then the Pom lawsuit comes out of left field and delays the national roll-out.
There are actually four parts to the original complaint by Pom Womderful.
1. Pompis is slang for "butt" which denigrates the Pom trademark
2. Second syllable sounds like "piss"
3. Pompis is tarnishing the health focused brand of Pom because as an energy drink it is unhealthful.
4. Design in lieu of the letter "0" could cause confusion.
All parts sound frivolous to me and the only parties that are going to benefit from this one year delay are the lawyers.
$18? That had to be before the OrBec trial was halted.
When are we going to hear what went wrong and a new trial started?
That is right, roll of the dice. However on PFOB I think that the odds are much better than 50-50 at this point. Not for those that want a quick buck but that have patience to wait it out.
Low float that is tightly held
One of these days I think we are going to get the news that we have been waiting for and the pps will bust loose.
Should be close now.......
That is good news. Let's see if we get a bump from this.
If Orbec is back in play then we will have a good chance of getting the share price back up to historic levels. We need news on Orbec.
Ask now at .039!
Moving on up
Try pompisenergy.com
Yes higher volume but the price went down. It is hard to believe that anyone would let their shares go so cheaply. Our day on the sun will happen.
It wouldn't matter much because as you stated the trial will be over in a month anyway.
Any positive news from Holigan and we are on our way but until then we are stuck at the gate.
Agree, how can you meet the endpoints when you only have 54% compliance on a clinical trial.
Now if they would just finish analyzing the data from the stage III trial we might go up a little.
bacc, I would not be too concerned about the day to day fluctuations in price at this point. We are trading in a range until we hear something definitive from Holigan. We could have another 500 share trade today at .02 which wouldn't mean a thing either.
I am hoping to hear news soon after the Pom lawsuit is settled.
I would like to see them move into the California market which as everyone knows has a very large Hispanic population. That would be the next likely state for distribution of Pompis.
Nope my first sell is at 10 cents to recover my initial investment. Then I will ride the free shares into dollarland!
Bama, great post. You are doing a good job as mod here. I don't post much anymore but still have a large position for the reasons that you mentioned in your post.
Holigan is no flash in the pan. He has built several successful businesses from the ground up and I have confidence in him to see this through which will create a nice payday for us longs.
It is my opinion that once the shell 'is cleaned up' he will move quickly to use it. As most here know a shell by itself does not generate revenue but needs to have an operating company RM'ed into it. Then he can take advantage of the benefits of the company being public especially in the area of raising capital to expand the business.
I believe that our long wait will yield results.
Probably just someone going to cash like a lot of folks that I know.
Me, I have decided to ride out the storm, let's see who made the wisest choice.
Once the 'crises' is behind us and the economy is not so lethargic money will flow back into equities. Until then we see lots of volatility.
Yep, those are the reasons that I am here.
Fully loaded and waiting for liftoff.
Me too. Played it last week for a 24% gain and bought a bunch this morning for the next run. This one could be flipped or held for several months.
August should be a good month for FCSC when they come out of their shell and announce what they have been planning for the last 2 months.
Financing, buyout, partnership, I will take any one of these.
Good find, Bama.
Grocers Supply is huge in Houston. Did some IT work for a grocery store there and they ordered just about all of the non-perishable food items from them.
I noticed also that on Page 1 that Pompis is one of the 5 main sponsors of the Food Show.
We are up 6% on a down day in the markets.
August should be a good month for us.
How could the stock be up today when a dead woman was found at the CEO's house.
Nude woman found dead
.695 Volume really picking up here.
Bottom feeders moving in for a bounce.
I hope so because this has has done nothing but go down since the FDA approval. We need a catalyst to initiate a trend reversal and a partnership announcement should do it.
TSPT-June 29, 2011
Transcept Pharmaceuticals upgraded to Buy from Neutral at Lazard Capital
Lazard Capital upgraded Transcept Pharmaceuticals with a $29 price target citing expectations the FDA will approve the company's insomnia treatment Intermezzo on the July 14 PDUFA date. :theflyonthewall.com
I agree that it is oversold given that LaViv was approved. Some sell on the news was bound to occur but come on, LaViv has a bright future.
It was 1.42 about a month ago and now we have .95? Most of these plays go up based on forward looking catalysts and when the catalyst has occurred then they sell forcing the price back down. The unknown factor is how many new investors will then come in based on approval and drive the price back up.
We shall see.....................
I disagree. The reason they had problems in the UK is they rolled it out too fast and some of the doctors did not apply the product correctly. Better to start slowly with handpicked group of quality doctors and then when the results are as expected then ramp up production. There are many examples like the UK one. Growing cell cultures are a bit more complicated than mousetraps and ours is FDA approved.
Yeah, but look at the longterm outlook, potentially $500M/year
Yes, it has been a very long time, but this is one that I have put on the back burner and some day it will hopefully boil over with newsworthy events that will make us all shout with glee and fill our wallets with gobs of cash.
Or something like that.......
Well look at the bright side, at least it is not drifting down over time like 95% of these pennies do. So we are not losing money, we are just not making any, yet.
In the meantime Pompis is generating revenue and expanding into new markets at a rapid clip. Let us hope for the coming together of PFOB and Pompis in the near future.
The selling is relentless here. Can't wait until July 7 so we can get the conversion mess behind us and move forward.
I hope the CEO puts out a PR soon saying that doctors are performing the procedure and bringing in revenue.
What I would like to see are more analysts giving it a buy rating with a high price target. Being on the OTC might be a limiting factor for this and also for institutional buying.
What I see in the next 3 months are more articles in beauty magazines, 30 doctors performing the treatment which will bring in much needed revenue, secondary offering or PP to raise cash.
Longer term (next year possibly), we should see an uplisting to a better exchange.
We have a very competent CEO and a hot sector that has been expanding over the last 3 years even during the recession.
In 2010, 13.1 million cosmetic plastic surgery procedures — including those that are minimally invasive or surgical — were performed in the U.S., according to the American Society of Plastic Surgeons. That’s a 5 percent increase from 2009. Face-lifts rose 9 percent, with 113,000 procedures.
Baby boomers take extreme measures to erase those wrinkles
Allure magazine article
Allure article
10.36 TSPT is starting another run here. After FCSC decision I think more money will roll over into this one and it moves fast with the low float.
Transcept shares became a Zacks #1 Rank on May 19.
Zacks Investment Ideas Feature Highlights: A123 Systems, Polypore, Ener1 and Johnson Controls
Date : 06/16/2011 @ 9:30AM
Source : PR Newswire
Stock : Transcept Pharmaceuticals, Inc. (MM) (TSPT)
Quote : 10.2025 0.3225 (3.26%) @ 7:26AM
Zacks Investment Ideas Feature Highlights: A123 Systems, Polypore, Ener1 and Johnson Controls
Transcept Pharmaceuticals, Inc. (MM) (NASDAQ:TSPT)
Intraday Stock Chart
Today : Thursday 16 June 2011
Click Here for more Transcept Pharmaceuticals, Inc. (MM) Charts.
Today, Zacks Investment Ideas feature highlights Features: Intermune (Nasdaq: ITMN), Raptor Pharmaceutical Corp (Nasdaq: RPTP), and Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT).
(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)
Biotech Lottery Tickets
Small biotech stocks are often considered "binary" lottery-ticket type events, with either a small chance of big upside, or a much greater probability of nothing at all. I call them "bipolar" because around FDA clinical trials and approval events, these stocks can soar to heights of euphoria and crash to depths of depression -- sometimes all in the same week.
Intermune (Nasdaq: ITMN) is an example from last year that stands out. The stock soared from $15 to nearly $50 last spring on positive expectations from FDA trials for its drug pirfenidone to treat idiopathic pulmonary fibrosis (IPF). IPF is a rare and fatal lung disease affecting more than 200,000 patients in Europe and the United States combined, with a survival rate of only 20 percent after five years.
But then subsequent findings of an FDA advisory panel were not as rosy and the stock plummeted back down to the teens within two months. Investors were taken for a while ride in a very short time and many probably swore they would never touch another small cap biotech with unproven medicine again. A few months later in December, ITMN launched back up to $40 on progress at meeting FDA hurdles for the drug.
Small Cap Biotechs to Watch: Raptor and Transcept
To give you an idea of how early and wrong you can be in these names sometimes, I bought Raptor Pharmaceutical Corp (Nasdaq: RPTP) in 2007 (before I became a Zacks Rank student) when it fell from $8 to $3. As its patented human receptor-associated protein (RAP) therapies designed to target cancer, neurodegenerative disorders and infectious diseases were still proving their science, the stock subsequently fell below 50 cents for most of 2009.
Then the fourth quarter of 2009 brought some good news and an instant spike back up to $4. Great, we're off to the races for riches, right? Not so fast. Over the next six months Raptor drifted back below $2 and I think I finally threw in the towel, selling my 500 shares at a loss when I consolidated some trading accounts last year.
I really wish I had held on for the measly $1,000 I had a risk. The past year has been steadily good to Raptor shares, and the past two months have seen a big move from below $4 up to nearly $6.50 on positive reactions from analysts about the company's strategy to focus on so-called "orphan" disease treatments.
Orphan diseases are generally defined as those afflicting less than 200,000 patients and both the US and EU grant special incentives for orphan drug development, often lessening time to market, development costs, and risks. Raptor's lead orphan drug is DR Cysteamine for the treatment of nephropathic cystinosis, a genetic disease marked by abnormal buildup of cysteine in the cells which can result in organ and brain damage.
As David Miller and Alan Leong of Biotech Stock Research suggest, investors don't pay enough attention to companies focused on orphan diseases because they tend to seek the "grand slam" block buster drug successes. Orphan diseases may offer less reward, but they also carry less risk and may lead to a steadier, more-predictable stream of sales.
Early on in the 80% move higher in Raptor shares in the past month was a boost in the Zacks Rank to a #2 position (buy) on May 17. The stock has received this #2 Rank only one other time since January 2009, when #3 Rank (hold) and #4 Rank (sell) ratings have dominated.
Though analysts still don't see the company being profitable in 2012, the outlook is for increased revenues coming from its drug pipeline and business strategies. Some larger investors must like the news too as the stock was on the receiving end of three 2-million share upside trading days during this time.
Currently, the Zacks target price for RPTP shares is only $6.50 as the revenue and earnings picture doesn't hold significant upside from what has already been quickly priced into the stock. The company is currently in Phase 3 clinical trials for DR Cysteamine and expects to report the data from this trial by the end of July 2011. Keep an eye on this name around late July to see how analysts react to the research outcomes and what corresponding shifts take place in the Zacks Rank.
Getting Back to Sleep Could Be Big Business
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) has an insomnia drug that looks poised to wake up revenues pretty quickly over the next few years if they pass muster with the FDA in July. Intermezzo is a crucial alternative to drugs like Ambien and Lunesta, which require at least seven hours for sleep, because it is designed to treat middle-of-the-night (MOTN) waking.
Those two extremely popular prescriptions have been found being used by patients at their doctors' recommendation during the MOTN and this poses serious threats to safety in early morning commutes. An FDA approval of Intermezzo could provide physicians a safer alternative, especially as early testing in actual highway driving studies is very encouraging.
Transcept shares became a Zacks #1 Rank on May 19 for the first time in our coverage as the two analysts on this name raised their earnings estimates from consensus EPS of $0.49 for this year to $0.95. They also boosted their consensus to $0.32 from a loss of 2 cents for 2012.
As Bill Wilton reported for Zacks on May 23, "They currently have $63.3 million left in cash and are averaging about $1.6 million per month in spending. Transcept brought in $3.1 million in revenue for the period from a license fee. That 24-month non-refundable fee has been coming in since August 2009 and will total $25 million when completed."
The drop-off in 2012 earnings is due to the end of that licensing fee. But analysts expect that FDA approval of Intermezzo will give Transcept a new valuation level to fit with strong growth into 2013 where full-year EPS estimates are as high as $0.97.
Investors should stay tuned to July 14 for the FDA announcement and watch the Zacks Rank as well. Expect new analysts to initiate coverage as this company and its science gain more attention.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.
Then when changes are discovered, they're applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell, and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter Profit from the Pros. In short, it's your steady flow of profitable ideas GUARANTEED to be worth your time. Get your free subscription to Profit from the Pros at: http://at.zacks.com/?id=7298
Follow us on Twitter: http://twitter.com/ZacksResearch
Join us on Facebook: http://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.com http://www.zacks.com
SOURCE Zacks Investment Research, Inc.